Buyadaa O, et al. – Researchers studied the rate of progression of nonalbuminuric chronic kidney disease (CKD) to end-stage kidney disease (ESKD) or death or major cardiovascular events (MACE) compared with albuminuric and nonalbuminuric phenotypes. The study sample consisted of over 10,100 participants with type 2 diabetes enrolled in the Action to Control Cardiovascular Risk in Diabetes study. According to findings, the rates of eGFR decline were −1.31 and −0.60 mL/min/year, respectively, for people with no CKD and those with nonalbuminuric CKD. Those with nonalbuminuric CKD exhibited a slower rate of eGFR decline than any other group. However, the investigators concluded, that these people still carry a greater risk of death and MACE than those without CKD.